TRV130

TRV130

TRV130
Systematic (IUPAC) name
[(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine
Clinical data
Legal status
  • Investigational
Routes of
administration
IV
Identifiers
ATC code None
Chemical data
Formula C22H30N2O2S
Molecular mass 386.55 g·mol−1

TRV130 is an opioid drug that is under evaluation in human clinical trials for the treatment of acute severe pain. It is a functionally selective μ-opioid receptor agonist developed by Trevena Inc. TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin 2 recruitment and receptor internalization, it displays less adverse effects than morphine.[1][2][3]

References

  1. ^
  2. ^
  3. ^

External links

  • Trevena: TRV130